| scholarly article | Q13442814 |
| P50 | author | Pierre Druilhe | Q80328511 |
| P2093 | author name string | Theisen M | |
| Diallo D | |||
| Corradin G | |||
| Meraldi V | |||
| Moret R | |||
| Nebié I | |||
| Sanogo E | |||
| Sirima BS | |||
| Tiono AB | |||
| P2860 | cites work | Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). | Q48039769 |
| Chemical characterization of the parasitophorous vacuole membrane antigen QF 116 from Plasmodium falciparum | Q57078114 | ||
| Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum | Q33591313 | ||
| Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. | Q34007707 | ||
| Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam | Q34008262 | ||
| Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity | Q34008755 | ||
| Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal | Q39515540 | ||
| Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages | Q41835030 | ||
| Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes | Q42938913 | ||
| Naturally acquired antibodies to the glutamate-rich protein are associated with protection against plasmodium falciparum malaria | Q46163143 | ||
| Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections | Q46184700 | ||
| Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. | Q46334562 | ||
| Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody | Q48003817 | ||
| Plasmodium falciparum: exported protein-1, a blood stage antigen, is expressed in liver stage parasites | Q48012562 | ||
| Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein | Q48027464 | ||
| P433 | issue | 6-7 | |
| P921 | main subject | antibody | Q79460 |
| Plasmodium falciparum | Q311383 | ||
| P304 | page(s) | 265-272 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Parasite Immunology | Q15751559 |
| P1476 | title | Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection | |
| P478 | volume | 26 |
| Q33987686 | A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children |
| Q47973517 | A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate |
| Q35016677 | Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic |
| Q36625461 | Antibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living in hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areas |
| Q40059998 | Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso |
| Q43245288 | Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. |
| Q36594057 | Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria |
| Q36304641 | Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso |
| Q36862490 | Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children |
| Q24815535 | Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission |
| Q39230991 | Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance |
| Q39006906 | Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates |
| Q40159945 | Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite |
| Q48023074 | Genetic Diversity of the Plasmodium falciparum Glutamate-Rich Protein R2 Region Before and Twelve Years after Introduction of Artemisinin Combination Therapies among Febrile Children in Nigeria |
| Q36838314 | How Should Antibodies against P. falciparum Merozoite Antigens Be Measured? |
| Q36421572 | Humoral responses to plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. |
| Q36984161 | Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development |
| Q33305467 | Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. |
| Q46583308 | Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya |
| Q35990786 | Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. |
| Q35216634 | New antigens for a multicomponent blood-stage malaria vaccine |
| Q35961275 | Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities |
| Q92071485 | Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines |
| Q34215916 | Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP). |
| Q35060442 | Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains |
| Q35094826 | Protection of Malian children from clinical malaria is associated with recognition of multiple antigens |
| Q56345699 | SURGE complex of Plasmodium falciparum in the rhoptry-neck (SURFIN4.2-RON4-GLURP) contributes to merozoite invasion |
| Q38995083 | Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate |
| Q41877888 | Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon |
| Q41233891 | Salmonella flagellin is a potent carrier-adjuvant for peptide conjugate to induce peptide-specific antibody response in mice |
| Q35853662 | Sero-epidemiological evaluation of Plasmodium falciparum malaria in Senegal |
| Q36953171 | Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria |
| Q22061950 | Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate |
| Q92636818 | Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model |
| Q37188653 | The C-terminal domain of Plasmodium falciparum merozoite surface protein 3 self-assembles into alpha-helical coiled coil tetramer |
| Q38658724 | The GMZ2 malaria vaccine: from concept to efficacy in humans. |
| Q33512926 | The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria |
| Q33526349 | The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis |
| Q33587443 | Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model |
Search more.